Author

N. Vasan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Assay:CRISPR screen· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

B. Izar· 2 shared J. C. Melms· 2 shared M. Mu· 2 shared P. Ho· 2 shared A. Ciccia· 1 shared A. D. Amin· 1 shared B. D. Hopkins· 1 shared B. T. Fullerton· 1 shared

Activity by Year

2022-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 32 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

B. Izar

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Massively parallel base editing screens to map variant effects on anti-tumor hallmarks of primary human T cells

Z. H. Walsh, P. Shah, N. Kothapalli, G. Nikolenyi, S. Shah, G. Leuzzi, M. Mu, P. Ho, S. Abuzaid, Z. D. Brodtman, N. Vasan, M. N. AlQuaraishi, J. D. Milner, A. Ciccia, J. C. Melms, B. Izar

This study uses base editing to screen for variants affecting T cell anti-tumor functions, identifying mutations that enhance tumor elimination with minimal off-target effects.

bioRxiv · Dec 13, 2023 · PreprintImmunology

Epinephrine inhibits PI3K alpha via the Hippo kinases.

T.-Y. Lin, S. Ramsamooj, K. Liberatore, L. Lantier, N. Vasan, K. Karukurichi, S.-K. Hwang, E. A. Kesicki, E. R. Kastenhuber, T. Wiederhold, T. M. Yaron, M. Zhu, Y. Ma, M. N. Paddock, G. Zhang, , M. D. Goncalves

The paper identifies Hippo kinases as inhibitors of PI3K alpha, showing epinephrine activates these kinases to suppress insulin signaling and glucose metabolism.

bioRxiv · Jul 19, 2022 · PreprintPhysiology

The CD58:CD2 axis is co-regulated with PD-L1 via CMTM6 and governs anti-tumor immunity

P. Ho, J. C. Melms, M. Rogava, C. J. Frangieh, S. B. Shah, Z. Walsh, O. Kyrysyuk, A. D. Amin, L. Caprio, B. T. Fullerton, R. Soni, C. R. Ager, J. Biermann, Y. Wang, M. Mu, , B. Izar

The paper identifies the CD58:CD2 axis as co-regulated with PD-L1 via CMTM6 and shows its role in anti-tumor immunity, proposing therapeutic strategies to enhance immunotherapy.

bioRxiv · Mar 21, 2022 · PreprintCancer Biology